Physician profile
Wilma E Walker
NPI 1144375262
$925.71
in general payments reported to CMS, 2019-2025
12 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.40 · 2022: $156 · 2023: $71.47 · 2024: $308 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $267.73 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $193.84 | 2022-2024 | Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $192.46 | 2022-2025 | Hetlioz, Fanapt |
| E.R. Squibb & Sons, L.L.C. | $55.34 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $43.71 | 2021 | |
| Avanir Pharmaceuticals, INC. | $43.48 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.24 | 2024 | |
| Abbvie INC. | $24.68 | 2021 | |
| Aimmune Therapeutics, INC. | $20.52 | 2024 | |
| Alkermes, INC. | $19.85 | 2022 | |
| Almatica Pharma LLC | $18.17 | 2024 | Loreev Xr |
| Pfizer INC. | $15.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilma Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.